Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/16/24
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking TherapeuticsThe Motley Fool • 04/05/24
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?The Motley Fool • 03/29/24
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?The Motley Fool • 03/19/24
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingGlobeNewsWire • 03/19/24
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?The Motley Fool • 03/17/24
Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soarProactive Investors • 03/15/24
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver diseaseCNBC • 03/14/24
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASHMarket Watch • 03/14/24
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisGlobeNewsWire • 03/14/24